BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Phase 3CompletedNCT01575054

Allergan468 enrolled

Overview

This study will evaluate the safety and efficacy of BOTOX® in the treatment of adult post-stroke lower limb spasticity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

468

Conditions

Muscle Spasticity

Interventions

botulinum toxin Type ABIOLOGICAL

Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.

Normal SalineDRUG

Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of post-stroke lower limb spasticity for at least 3 months * Minimum body weight of 50 kg * Never treated with botulinum toxin of any serotype for any reason, or if previously treated with botulinum toxin of any serotype, if previously treated for spasticity in the affected lower limb, must have been administered * 20 weeks before Day 1, or if previously treated for any other indication must have been administered ≥12 weeks prior to Day 1 Exclusion Criteria: * Spasticity in the opposite leg that requires treatment * Casting of the study limb within 6 months or planned casting during the first 12 weeks of the study * Treatment modalities in the study limb including ultrasound, electrical nerve stimulation, electrical stimulation, acupuncture within 1 month of Day 1 or treatments planned during the study * Not able to perform 10 meter walking test independently with or without assistive device * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

Locations (12)

Unnamed facility

Downey, California, United States

Unnamed facility

Daytona Beach, Florida, United States

Unnamed facility

Montreal, Quebec, Canada

Unnamed facility

Prague, Czechia

Outcomes

Primary Outcomes

Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale

The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the ankle flexors by passively moving the ankle plantar flexor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. The average of the weeks 4 and 6 MAS-B ankle change from baseline is the primary end point. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.

Time frame: Baseline, 6 Weeks

Secondary Outcomes

Clinical Global Impression (CGI) of Overall Change by Physician Using a 9-Point Scale

The CGI is a 9-point scale evaluating change from baseline status by the Physician. Scores range from +4 (very marked improvement) to -4 (very marked worsening). The average of the weeks 4 and 6 CGI by Physician score is used as a secondary end point. Higher scores indicate a greater improvement from baseline.

Time frame: Baseline, 6 weeks

Goal Attainment Scores on the 6-Point Physician-Assessed Goal Attainment Scale (GAS)

The physician-assessed GAS is an individualized, goal-oriented 6-point scale used to track functional improvement toward active and passive goals. GAS scoring ranged from -3 to 2 (-3 = worse than start; 0 = expected goal/attained the defined therapeutic goal; 2 = much more than expected/improvements clearly exceeded the defined therapeutic goal). Active and Passive Goal scores are presented.

Time frame: Week 8

Change From Baseline in Average Pain Score While Walking on the 11-Point Pain Scale

The patient is asked to select a number that best describes his/her pain while walking on an 11-point scale from 0 = "no pain" to 10 = "pain as bad as can be imagined". Patients are instructed to recall their average pain in the study limb during the 48-hour period prior to the visit. Patients with a baseline pain score \>0 are included in the analyses.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.